Finland's Orion Q1 net sales rise on Nubeqa growth

Orion Oyj

23/04/2026 10:10

Overview

Finland pharmaceutical firm's Q1 net sales rose 17.8% yr/yr to EUR 417.7 mln

Q1 operating profit and basic EPS both rose 47% yr/yr

Company raised lower end of 2026 net sales and operating profit outlook ranges

Outlook

Orion sees 2026 net sales at EUR 1,950 mln to EUR 2,100 mln

Company expects 2026 operating profit of EUR 600 mln to EUR 750 mln

Orion expects R&D and sales and marketing expenses to increase in 2026

Result Drivers

NUBEQA GROWTH - Co said both royalties and product sales from Nubeqa rose significantly yr/yr, supporting group results

EASYHALER PORTFOLIO - Growth in Branded Products division driven by Easyhaler portfolio, supported by shift to combination therapy

CONSUMER HEALTH OUTPACES GENERICS - Consumer Health grew faster than Generics within the Generics and Consumer Health division

Company press release: ID:nGNE8mGZZr

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
EUR 417.70 mln
Q1 Net Income
EUR 90.40 mln
Q1 Basic EPS
EUR 0.64
Q1 Operating Profit
EUR 114.80 mln
Q1 Pretax Profit
EUR 113.40 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Orion Oyj is €78.00, about 6.3% above its April 22 closing price of €73.35

The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 18 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)